- •Abbreviations
- •1 Overview of Antimicrobial Therapy
- •Factors in Antibiotic Selection
- •Factors in Antibiotic Dosing
- •Microbiology and Susceptibility Testing
- •PK/PD and Other Considerations in Antimicrobial Therapy
- •Antibiotic Failure
- •Pitfalls in Antibiotic Prescribing
- •References and Suggested Readings
- •2 Empiric Therapy Based on Clinical Syndrome
- •Empiric Therapy of CNS Infections
- •Empiric Therapy of HEENT Infections
- •Empiric Therapy of Lower Respiratory Tract Infections
- •Empiric Therapy of GI Tract Infections
- •Empiric Therapy of Genitourinary Tract Infections
- •Empiric Therapy of Sexually Transmitted Diseases
- •Empiric Therapy of Bone and Joint Infections
- •Empiric Therapy of Skin and Soft Tissue Infections
- •Sepsis/Septic Shock
- •Febrile Neutropenia
- •Transplant Infections
- •Toxin-Mediated Infectious Diseases
- •Bioterrorist Agents
- •References and Suggested Readings
- •Gram Stain Characteristics of Isolates
- •Parasites, Fungi, Unusual Organisms in Blood
- •Parasites, Fungi, Unusual Organisms in CSF/Brain
- •Parasites, Fungi, Unusual Organisms in Lungs
- •Parasites, Fungi, Unusual Organisms in Heart
- •Parasites, Fungi, Unusual Organisms in the Liver
- •References and Suggested Readings
- •5 HIV Infection
- •HIV Infection Overview
- •Stages of HIV Infection
- •Acute (Primary) HIV Infection
- •Initial Assessment of HIV Infection
- •Indications for Treatment of HIV Infection
- •Antiretroviral Treatment
- •Treatment of Other Opportunistic Infections in HIV
- •HIV Coinfections (HBV/HCV)
- •References and Suggested Readings
- •6 Prophylaxis and Immunizations
- •Surgical Prophylaxis
- •Post-Exposure Prophylaxis
- •Chronic Medical Prophylaxis
- •Endocarditis Prophylaxis
- •Travel Prophylaxis
- •Tetanus Prophylaxis
- •Immunizations
- •References and Suggested Readings
- •Empiric Therapy of CNS Infections
- •Empiric Therapy of HEENT Infections
- •Empiric Therapy of Lower Respiratory Tract Infections
- •Empiric Therapy of Vascular Infections
- •Empiric Therapy of Gastrointestinal Infections
- •Empiric Therapy of Bone and Joint Infections
- •Empiric Therapy of Skin and Soft Tissue Infections
- •Common Pediatric Antimicrobial Drugs
- •References and Suggested Readings
- •8 Chest X-Ray Atlas
- •References and Suggested Readings
- •9 Infectious Disease Differential Diagnosis
- •11 Antimicrobial Drug Summaries
- •Appendix
- •Malaria in Adults (United States)
- •Malaria in Children (United States)
- •Index
Chapter 2. Empiric Therapy Based on Clinical Syndrome |
151 |
Pubic Lice (Phthirus pubis) Crabs
Clinical Presentation: Genital pruritus..
Diagnostic Considerations: Seen on groin, eyelashes, axilla.. May survive away from body × 1 day.. Pitfalls: Smaller than head lice, but easily seen..
Therapeutic Considerations: Treat partners.. Wash, dry, and iron clothes; heat from dryer/iron kills lice.. Non-washables may be placed in a sealed bag × 7 days..
Prognosis: Good if clothes are also treated..
Ischiorectal/Perirectal Abscess
Subset |
Pathogens |
Preferred Therapy |
|
|
|
Ischiorectal/ |
Enterobacteriaceae |
Treat the same as mild/severe peritonitis (p.. 100) ± surgical |
perirectal |
B.. fragilis |
drainage depending on abscess size/severity |
abscess |
|
|
|
|
|
Clinical Presentation: Presents in normal hosts with perirectal pain, pain on defecation, leukocytosis, erythema/tenderness over abscess ± fever/chills.. In febrile neutropenia, there is only tenderness.. Diagnostic Considerations: Diagnosis by erythema/tenderness over abscess or by CT/MRI.. Pitfalls: Do not confuse with perirectal regional enteritis (Crohn’s disease) in normal hosts, or with ecthyma gangrenosum in febrile neutropenics..
Therapeutic Considerations: Antibiotic therapy may be adequate for mild cases. . Large abscesses require drainage plus antibiotics × 1–2 weeks post-drainage.. With febrile neutropenia, use an antibiotic that is active against both P.. aeruginosa and B.. fragilis e..g.., meropenem..
Prognosis: Good with early drainage/therapy..
Sepsis/Septic Shock
Sepsis/Septic Shock
|
Usual |
Preferred IV |
Alternate IV |
IV-to-PO |
Subset |
Pathogens |
Therapy |
Therapy |
Switch |
|
|
|
|
|
Unknown |
Entero- |
Meropenem 1 gm (IV) |
Quinolone* (IV) × |
Moxifloxacin |
source |
bacteriaceae |
q8h × 2 weeks |
2 weeks |
400 mg (PO) |
|
B.. fragilis |
or |
plus either |
q24h × 2 weeks |
|
E.. faecalis |
Piperacillin/ |
Metronidazole 1 gm |
|
|
(VSE)† |
tazobactam 3..375 gm |
(IV) q24h × 2 weeks |
|
|
|
(IV) q6h × 2 weeks |
or |
|
|
|
or |
Clindamycin 600 mg |
|
|
|
Moxifloxacin 400 mg |
(IV) q8h × 2 weeks |
|
|
|
(IV) q24h × 2 weeks |
|
|
|
|
|
|
|
VSE/VRE = vancomycin-sensitive/resistant enterococci. Duration of therapy represents total time IV or IV + PO..
*Ciprofloxacin 400 mg (IV) q12h or Levofloxacin 500 mg (IV or PO) q24h..
†Treat initially for E.. faecalis (VSE); if later identified as E.. faecium (VRE), treat accordingly (urosepsis see pp.. 154–155)..
152 A n t i b i o t i c E s s e n t i a l s
Sepsis/Septic Shock (cont’d)
|
Usual |
Preferred IV |
|
Alternate IV |
IV-to-PO |
Subset |
Pathogens |
Therapy |
|
Therapy |
Switch |
|
|
|
|
|
|
Lung source |
S.. pneumoniae |
Respiratory |
|
Any 2nd generation |
Respiratory |
Community- |
H.. influenzae |
quinolone‡ (IV) q24h |
|
cephalosporin (IV) |
quinolone‡ (PO) |
acquired |
K.. |
× 2 weeks |
|
× 2 weeks |
q24h ×2 weeks |
pneumonia§ |
pneumoniae** |
or |
|
|
or |
|
|
Ceftriaxone 1 gm |
|
|
Doxycycline |
|
|
(IV) q24h × 2 weeks |
|
|
200mg (PO) q12h |
|
|
|
|
|
×3 days, then |
|
|
|
|
|
100 mg (PO) q12h |
|
|
|
|
|
×11 days |
|
Influenza A |
MSSA/MRSA |
|
(see pp.. 62–63) |
(see p.. 52) |
|
(ILI with rapidly |
|
|
|
|
|
cavitating <72 |
|
|
|
|
|
hours multiple |
|
|
|
|
|
pulmonary |
|
|
|
|
|
infiltrates) |
|
|
|
|
|
|
|
|
|
|
Nosocomial |
P.. aeruginosa |
Same as ventilator-associated pneumonia (see p.. 68) |
|||
pneumonia |
K.. pneumoniae |
|
|
|
|
|
E.. coli |
|
|
|
|
|
S.. marcescens |
|
|
|
|
|
(not MSSA/ |
|
|
|
|
|
MRSA) |
|
|
|
|
CVC |
S.. epidermidis |
Meropenem 1 gm |
|
Ceftriaxone 1 gm (IV) |
Respiratory |
source*** |
(CoNS) |
(IV) q8h ×2 weeks |
|
q24h × 2 wks |
quinolone* (PO) |
Bacteremia |
S.. aureus (MSSA) |
or |
|
or |
q24h × 2 weeks |
(Treat initially |
Klebsiella |
Cefepime 2 gm (IV) |
|
Respiratory |
or |
Enterobacter |
q12h ×2 wks |
|
quinolone* (IV) q24h |
Cephalexin 500 |
|
for MSSA; if later |
|
||||
Serratia |
|
|
× 2 wks |
mg (PO) q6h × 2 |
|
identified as |
|
|
|||
|
|
|
|
weeks |
|
MRSA, etc.., treat |
|
|
|
|
|
accordingly) |
S.. aureus |
Daptomycin 6 mg/kg (IV) q24h × 2 weeks |
Linezolid 600 |
||
|
(MRSA) |
|
or |
mg (PO) q12h × |
|
|
|
Linezolid 600 mg (IV) q12h × 2 weeks |
2 weeks |
||
|
|
|
|
|
|
ILI = Influenza like illness..
MRSA/MSSA = methicillin resistant/sensitive S. aureus. Duration of therapy represents total time IV or IV + PO..
*Moxifloxacin 400 mg or Levofloxacin 500 mg.. ** In alcoholics only
***If clinically possible, remove CVC as soon as possible..
†Patients with ILI/influenza A (human/swine) presenting with simultaneous MSSA/MRSA CAP often present in shock..
‡Levofloxacin 750 mg (IV) q24h or Moxifloxacin 400 mg (IV) q24h..
§Uncomplicated by cardiopulmonary decompensation/failure, CAP does not present with hypotension/shock in normal hosts. Hyposplenia/asplenia should be suspected if CAP presents with hypotension/shock in patients with good cardiopulmonary function.
Chapter 2. Empiric Therapy Based on Clinical Syndrome |
153 |
Sepsis/Septic Shock (cont’d)
|
Usual |
Preferred IV |
Alternate IV |
IV-to-PO |
|
Subset |
Pathogens |
Therapy |
Therapy |
Switch |
|
|
|
|
|
||
|
|
Quinupristin/dalfopristin 7..5 mg/kg (IV) q8h |
Minocycline 100 |
||
|
|
× 2 weeks |
|
mg (PO) q12h × |
|
|
|
|
or |
2 weeks |
|
|
|
Vancomycin 1 gm (IV) q12h × 2 weeks |
|
||
Candidemia |
Candida |
If less critically ill, not neutropenic, and no |
Fluconazole 400 |
||
(disseminated/ |
albicans |
recent azole exposure: fluconazole is usual |
mg (PO) q24h |
||
invasive) |
(or other |
first choice alternates an echinocandin may |
× 2 weeks† or |
||
Unless species is |
fluconazole- |
be used.. |
|
Voriconazole |
|
susceptible |
In critically ill, neutropenia or recent azole |
(see “usual dose,” |
|||
known, empiric |
|||||
therapy as for |
species)¶ |
exposure: an echinocandin is preferred.. |
p.. 714) |
||
non-albicans/ |
|
or Micafungin 100 mg (IV) q24h ×2 weeks† or |
|
||
possibly |
|
Caspofungin 70 mg (IV) ×1 dose, then 50 mg |
|
||
fluconazole- |
|
(IV) q24h ×2 weeks† Fluconazole 800 mg (IV) |
|
||
resistant Candida |
|
×1, then 400 mg (IV) q24h ×2 weeks† or Lipid- |
|
||
is preferred if |
|
associated formulation of amphotericin B (p.. |
|
||
recent prior |
|
|
|||
|
525) (IV) q24h ×2 weeks† or Amphotericin B |
|
|||
azole therapy, |
|
|
|||
|
deoxycholate 0..7 mg/kg (IV) q24h ×2 weeks† |
|
|||
severe illness, |
|
|
|||
neutropenia |
|
orVoriconazole (see“usual dose,” p.. 714) or |
|
||
or high risk for |
|
Anidulafungin 200 mg (IV) ×1 dose, then 100 mg |
|
||
infection with |
|
(IV) q24h ×2 weeks† |
|
|
|
C.. glabrata or C.. |
|
|
|
|
|
Non-albicans |
Choices are as for C.. albicans (see above), |
Voriconazole |
|||
krusei |
|||||
Candida¶ |
but Fluconazole should not be used and an |
(see “usual dose,” |
|||
|
|||||
|
(possibly |
echinocandin is preferred.. Micafungin 100 |
p.. 714) × 2 |
||
|
fluconazole- |
mg (IV) q24h × 2 weeks† or Caspofungin (see |
weeks¶† |
||
|
resistant) |
C.. albicans, above) Use an Amphotericin or |
|
||
|
|
Voriconazole if additional mould coverage |
|
||
|
|
is desired or Lipid amphotericin B (p.. 525) |
|
||
|
|
(IV) q24h† or Amphotericin B deoxycholate |
|
||
|
|
(see C.. albicans, above) × 2 weeks† or |
|
||
|
|
Voriconazole (see “usual dose,” p.. 714) × 2 |
|
||
|
|
weeks¶† or Itraconazole (see C.. albicans, |
|
||
|
|
above) or Anidulafungin 200 mg (IV) × |
|
||
|
|
1 dose, then 100 mg (IV) q24h × 2 weeks† |
|
¶Best agent depends on infecting species. . Fluconazole-susceptibility varies predictably by species. . (See Fluconazole Drug Summary) also, see Amphotericin B (deoxycholate and lipid-associated formulations) Drug Summaries..
†Treat candidemia for 2 weeks after negative blood cultures..
154 A n t i b i o t i c E s s e n t i a l s
Sepsis/Septic Shock (cont’d)
|
Usual |
Preferred IV |
Alternate IV |
IV-to-PO |
Subset |
Pathogens |
Therapy |
Therapy |
Switch |
|
|
|
|
|
Intra- |
Entero- |
Ertapenem 1 gm |
Combination |
Moxifloxacin |
abdominal/ |
bacteriaceae |
(IV) q24h × 2 weeks |
therapy with |
400 mg (PO) |
pelvic source |
B.. fragilis |
or |
either |
q24h × |
|
|
Tigecycline 200 mg |
Ceftriaxone 1 gm (IV) |
2 weeks |
|
|
(IV) × 1 dose, then |
q24h × 2 weeks |
or |
|
|
100 mg (IV) q24h × |
combination |
|
|
|
2 weeks |
or |
therapy with |
|
|
Levofloxacin 500 mg |
||
|
|
or |
Levofloxacin |
|
|
|
(IV) q24h × 2 weeks |
||
|
|
Meropenem 1 gm |
500 mg (PO) |
|
|
|
plus |
||
|
|
(IV) q8h × 2 weeks |
q24h × 2 weeks |
|
|
|
Metronidazole 1 gm |
||
|
|
or |
plus |
|
|
|
(IV) q24h × 2 weeks |
||
|
|
Piperacillin/ |
Clindamycin |
|
|
|
|
||
|
|
tazobactam 3..375 |
|
300 mg (PO) |
|
|
gm (IV) q6h × |
|
q8h × 2 weeks |
|
|
2 weeks |
|
|
Urosepsis |
Entero- |
Levofloxacin |
Meropenem 1 gm |
Levofloxacin |
(community- |
bacteriaceae |
500 mg (IV) q24h |
(IV) q8h × 1–2 weeks |
500 mg (PO) |
acquired) |
E.. faecalis (VSE) |
× 1–2 weeks |
or |
q24h × 1–2 |
|
|
or |
Levofloxacin |
weeks |
|
|
Piperacillin/ |
||
|
|
500 mg (IV) q24h |
|
|
|
|
tazobactam 3..375 |
|
|
|
|
|
|
|
|
|
gm (IV) q6h |
|
|
|
|
× 1–2 weeks |
|
|
|
|
|
|
|
|
E.. faecium |
Daptomycin 6 mg/ |
Quinupristin/ |
Linezolid 600 |
|
(VRE) |
kg (IV) q24h × 1–2 |
dalfopristin |
mg (PO) q12h |
|
|
weeks |
7..5 mg/kg (IV) q8h |
×1–2 weeks |
|
|
or |
× 1–2 weeks |
or |
|
|
Minocycline 100 |
||
|
|
Linezolid 600 mg |
|
|
|
|
|
mg (PO) q12h × |
|
|
|
(IV) q12h × 1–2 |
|
|
|
|
|
1–2 weeks |
|
|
|
weeks |
|
|
|
|
|
|
|
(nosocomial) |
P.. aeruginosa |
Meropenem 1 gm |
Aztreonam 2 gm (IV) |
Levofloxacin |
|
Entero- |
(IV) q8h × 1–2 weeks |
q8h × 1–2 weeks |
750 mg (PO) |
|
bacteriaceae |
or |
or |
q24h × 1–2 |
|
Doripenem 1 gm (IV) |
|||
|
|
Cefepime 2 gm (IV) |
weeks |
|
|
|
q8h ×1–2 weeks |
||
|
|
q12h × 1–2 weeks |
|
|
|
|
or |
|
|
|
|
|
|
|
|
|
Levofloxacin 750 |
|
|
|
|
mg (IV) q24h × 1–2 |
|
|
|
|
weeks |
|
|
|
CRE |
Ceftazidime/ |
Colistin 5 mg/kg (IV) |
|
|
|
avibactam 2..5 gm |
q8h × 1–2 weeks |
|
|
|
(IV) q 8 h × 1–2 |
|
|
|
|
weeks |
|
|
|
|
|
|
|
Chapter 2. Empiric Therapy Based on Clinical Syndrome |
155 |
Sepsis/Septic Shock (cont’d)
|
Usual |
Preferred IV |
|
Alternate IV |
IV-to-PO |
Subset |
Pathogens |
Therapy |
|
Therapy |
Switch |
|
|
|
|
|
|
Urosepsis |
E.. faecalis (VSE) |
Ampicillin 2 gm (IV) q4h × 1–2 weeks |
Amoxicillin 1 gm |
||
(group D |
|
|
or |
(PO) q8h × 1–2 |
|
enterococci) |
|
Piperacillin/tazobactam 3..375 gm (IV) q6h × |
weeks |
||
|
|
1–2 weeks |
|
|
or |
|
|
or combination therapy with |
Levofloxacin 500 |
||
|
|
Vancomycin 1 gm (IV) q12h × 1–2 weeks |
mg (PO) q24h × |
||
|
|
|
plus |
1–2 weeks |
|
|
|
Gentamicin 240 mg (IV) q24h ×1 week |
|
||
|
|
|
|
|
|
|
E.. faecium |
Linezolid 600 mg (IV) q12h × 1–2 weeks |
Linezolid 600 |
||
|
(VRE) |
|
or |
mg (PO) q12h × |
|
|
|
Quinupristin/dalfopristin 7..5 mg/kg (IV) q8h |
1–2 weeks |
||
|
|
× 1–2 weeks |
|
|
or |
|
|
|
|
|
Minocycline 100 |
|
|
|
|
|
mg (PO) q12h × |
|
|
|
|
|
3 days, then 100 |
|
|
|
|
|
mg (PO) q12h × |
|
|
|
|
|
4–11 days |
|
|
|
|
|
|
Overwhelming |
S.. pneumoniae |
Ceftriaxone 2 gm |
|
Cefepime 2 gm (IV) |
Levofloxacin 500 |
sepsis with |
H.. influenzae |
(IV) q24h × 2 weeks |
|
q12h × 2 weeks |
mg (PO) q24h × |
purpura |
N.. meningitidis |
or |
|
or |
2 weeks |
(asplenia or |
|
Levofloxacin 500 mg |
|
Cefotaxime 2 gm (IV) |
or |
hyposplenia) |
|
(IV) q24h ×2 weeks |
|
q6h × 2 weeks |
Amoxicillin |
|
|
|
|
|
1 gm (PO) q8h × |
|
|
|
|
|
2 weeks |
|
|
|
|
|
|
Steroids (high |
Aspergillus |
Treat as Aspergillus pneumonia (see p.. 55) |
|
||
chronic dose) |
|
|
|
|
|
|
|
|
|||
Miliary TB |
M.. tuberculosis |
Treat as pulmonary TB (see p.. 53) plus steroids ×1–2 wks |
|||
|
|
|
|||
Miliary BCG |
Bacille |
Treat with INH plus RIF × 9 months; EMB, until susceptibilities |
|||
(disseminated |
Calmette- |
known; may add steroids e..g.., prednisolone 40 mg q24h × 1–2 |
|||
BCG) |
Guérin (BCG) |
weeks |
|
|
|
|
|
|
|
||
Septic shock |
Gram- |
Meropenem 1 gm (IV) q8h × 1-2 weeks* |
|
||
|
negative or |
|
|
|
|
|
gram-positive |
|
|
|
|
|
bacteria |
|
|
|
|
|
|
|
|
|
|
Duration of therapy represents total time IV or IV + PO.. * Plus surgical decompression/drainage if needed..
156 A n t i b i o t i c E s s e n t i a l s
Sepsis (Unknown Source)
Clinical Presentation: Abrupt onset of high spiking fevers, rigors ± hypotension..
Diagnostic Considerations: Diagnosis suggested by high-grade bacteremia (2/4–4/4 positive blood cultures) with unexplained hypotension.. Rule out pseudosepsis (GI bleed, myocardial infarction, pulmonary embolism, acute pancreatitis, adrenal insufficiency, etc..).. Sepsis usually occurs from a GI, GU, or IV source, so coverage is directed against GI and GU pathogens if IV line infection is unlikely..
Pitfalls: Most cases of fever/hypotension are not due to sepsis.. Before the label of “sepsis” is applied to febrile/hypotensive patients, first consider treatable/reversible mimics (see p.. 151)..
Therapeutic Considerations: Resuscitate shock patients initially with rapid adequate volume replacement, followed by pressors, if needed.. Do not give pressors before volume replacement or hypotension may continue/worsen.. Use normal saline, plasma expanders, or blood for volume replacement, not D5W.. If patient is persistently hypotensive despite volume replacement, consider relative adrenal insufficiency: Obtain a serum cortisol level, then give cortisone 100 mg (IV) q6h × 24–72h; blood pressure will rise promptly if relative adrenal insufficiency is the cause of volume-unresponsive hypotension.. Do not add/ change antibiotics if patient is persistently hypotensive/febrile; look for GI bleed, myocardial infarction, pulmonary embolism, pancreatitis, undrained abscess, adrenal insufficiency, or IV line infection.. Drain abscesses as soon as possible.. Remove IV lines if the entry site is red or a central line has been in place for ≥ 7 days and there is no other explanation for fever/hypotension.. Early antibiotic therapy/surgical drainage of abscesses, debridement of necrotic tissue eg.. necrotizing fasciitis or relief of obstruction is critical.. Prognosis: Related to severity of septic process and underlying cardiopulmonary/immune status..
Sepsis (Lung Source)
Clinical Presentation: Normal hosts with community-acquired pneumonia (CAP) do not present with sepsis. . CAP with sepsis suggests the presence of impaired immunity/hyposplenic function (see “sepsis in hyposplenia/asplenia,” p. . 157). . Nosocomial pneumonia uncommonly presents as (or is complicated by) sepsis with otherwise unexplained hypotension..
Diagnostic Considerations: Impaired splenic function may be inferred by finding Howell-Jolly bodies (small, round, pinkish or bluish inclusion bodies in red blood cells) in the peripheral blood smear.. The number of Howell-Jolly bodies is proportional to the degree of splenic dysfunction..
Pitfalls: CAP with hypotension/sepsis should suggest hyposplenic function, impaired immunity, or an alternate diagnosis that can mimic CAP/shock.. Be sure to exclude acute MI, acute heart failure/COPD, PE/ infarction, overzealous diuretic therapy, concomitant GI bleed, and acute pancreatitis..
Therapeutic Considerations: Patients with malignancies, myeloma, or SLE are predisposed to CAP, which is not usually severe or associated with shock.. Be sure patients with CAP receiving steroids at less than “stress doses” do not have hypotension/shock from relative adrenal insufficiency.. In patients with SLE, try to distinguish between lupus pneumonitis and CAP; SLE pneumonitis usually occurs as part of a SLE flare, CAP usually does not..
Prognosis: Related to underlying cardiopulmonary/immune status.. Early treatment is important..
Sepsis (Central Venous Catheter [CVC] Source)
Clinical Presentation: Temperature ≥ 102°F ± IV site erythema..
Diagnostic Considerations: Diagnosis by semi-quantitative catheter tip culture with ≥ 15 colonies plus blood cultures with same pathogen.. If no other explanation for fever and line has been in place ≥ 7 days, remove CVC and obtain semi-quantitative catheter tip culture.. Suppurative thrombophlebitis presents with hectic/septic fevers and pus at IV site ± palpable venous cord..
Chapter 2. Empiric Therapy Based on Clinical Syndrome |
157 |
Pitfalls: Temperature ≥ 102°F with CVC infection, in contrast to phlebitis (temperature ≤ 102°F).. Acute bacterial endocarditis (ABE) may complicate intracardiac or CVC (not peripheral) infection.. Therapeutic Considerations: Line removal is usually curative, but antibiotic therapy is usually given for 1 week after CVC removal for gram-negative bacilli or 2 weeks after CVC removal for S.. aureus (MSSA/ MRSA).. Antifungal therapy is also usually given for 2 weeks after CVC removal for candidemia.. Dilated ophthalmoscopy by an ophthalmologist is important to exclude candidal endophthalmitis following candidemia..
Prognosis: Good if CVC is removed before endocarditis/metastatic spread..
Sepsis (Intra-abdominal/Pelvic Source)
Clinical Presentation: Fever, peritonitis ±hypotension.. Usually a history of an intra-abdominal disorder that predisposes to sepsis (e..g.., diverticulosis, gallbladder disease, recent intra-abdominal/pelvic surgery).. Signs and symptoms are referable to the abdomen/pelvis..
Diagnostic Considerations: Clinical presentation plus imaging studies (e..g.., abdominal/pelvic CT or MRI to demonstrate pathology) are diagnostic..
Pitfalls: Elderly patients may have little/no fever and may not have rebound tenderness.. Be sure to exclude intra-abdominal mimics of sepsis (e..g.., GI bleed, pancreatitis)..
Therapeutic Considerations: Empiric coverage should be directed against aerobic gram-negative bacilli plus B.. fragilis.. Anti-enterococcal coverage is not essential.. Antibiotic therapy is ineffective unless ruptured viscus is repaired, obstruction is relieved, abscesses are drained..
Prognosis: Related to rapidity/adequacy of abscess drainage and repair/lavage of ruptured organs.. The preoperative health of the host is also important..
Sepsis (Urinary Source)
Clinical Presentation: Fever/hypotension in a patient with diabetes mellitus, SLE, myeloma, pre-exist- ing renal disease, stone disease, or partial/total urinary tract obstruction..
Diagnostic Considerations: Urine gram stain determines initial empiric coverage.. Pyuria is also present.. Diagnosis confirmed by culturing the same isolate from urine and blood..
Pitfalls: Pyuria without bacteriuria and bacteremia due to same pathogens is not diagnostic of urosepsis.. Urosepsis does not occur in normal hosts; look for host defect (e..g.., diabetes, renal disease).. Therapeutic Considerations: If stones/obstruction are not present, urosepsis resolves rapidly with appropriate therapy.. Delayed/no response suggests infected/obstructed stent, stone, partial/total urinary tract obstruction, or renal abscess..
Prognosis: Good if stone/stent removed, obstruction relieved, abscess drained.. Fatalities rare with urosepsis..
Sepsis (Hyposplenia/Asplenia)
Clinical Presentation: Presents as overwhelming septicemia/shock with petechiae..
Diagnostic Considerations: Diagnosis by gram stain of buffy coat of blood or by blood cultures.. Organism may be stained/cultured from aspirated petechiae.. Howell-Jolly bodies in the peripheral smear are a clue to decreased splenic function.. Conditions associated with hyposplenism include sickle cell trait/disease, cirrhosis, rheumatoid arthritis, SLE, systemic necrotizing vasculitis, amyloidosis, celiac disease, chronic active hepatitis, Fanconi’s syndrome, IgA deficiency, intestinal lymphangiectasia, intravenous gammaglobulin therapy, myeloproliferative disorders, non-Hodgkin’s lymphoma, regional enteritis, ulcerative colitis, Sezary syndrome, splenic infarcts/malignancies, steroid therapy, systemic mastocytosis, thyroiditis, infiltrative diseases of spleen, mechanical compression of splenic artery/spleen, Waldenstrom’s macroglobulinemia, hyposplenism of old age, congenital absence of spleen..
Pitfalls: Suspect hyposplenia/asplenia in unexplained overwhelming infection..